TY  - JOUR
T1  - Calcitonin-Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention; Literature Review
A1  - Haneen Ahmed Khouja
A1  - Rawan Awadh Alshehri
A1  - Hussain Mirza Alhalal
A1  - Hassan Dhafer Alabisi
A1  - Salhah Mohammad Alajmi
A1  - Zahra Moneer Al Radi
A1  - Zainab Abduljabbar Al Hamoud
A1  - Asma Wadi Zaid Alshammari
A1  - Danah Youssef A Albouri
A1  - Abrar Talat Saeed Aleysawi
A1  - Raghad Khalid Alammari
JF  - World Journal of Environmental Biosciences
JO  - World J Environ Biosci
SN  - 2277-8047
Y1  - 2021
VL  - 10
IS  - 1
DO  - 10.51847/ogC7ozOJpH
SP  - 48
EP  - 51
N2  - Migraine is one of the most common disabling disorders worldwide that influence the patient functionality and quality of life. Current preventive therapy has succeeded in preventing and decreasing migraine days; however, unwanted adverse effects are considered a serious issue and can lead to discontinuation of the medication. The calcitonin-gene-related peptide is a neuropeptide that plays a major role in migraine pathogenesis, and inhibiting this peptide is thought to achieve a therapeutic role in migraine prevention.  This literature review aims to review the role of this peptide in migraine pathogenesis and the implementation of monoclonal antibodies in migraine preventive therapy.  A relevant articles were collected from the PubMed database, using the following Mesh words: Calcitonin-gene-related peptide, migraine, migraine prevention. Calcitonin-gene-related peptide monoclonal antibodies seem to have a significant therapeutic role in migraine prevention. Few side effects were reported, of which infection was the common reported one. The long-term safety profile has not been evaluated up to our knowledge. Therefore, a long-term safety assessment would be required in addition to comparison with the standard migraine preventive therapy.
UR  - https://environmentaljournals.org/article/calcitonin-gene-related-peptide-cgrp-monoclonal-antibodies-in-migraine-prevention-literature-revi-hrc6bgjul6jwbbw
ER  -